English Overview
The EbGlyss launch event aims to introduce healthcare professionals to a novel therapeutic option in the treatment of atopic dermatitis . This activity will provide a comprehensive overview of the clinical profile of EbGlyss (lebrikizumab), including its mechanism of action, efficacy and safety data, patient selection criteria, and its role in current treatment paradigms. The launch will also highlight unmet needs in dermatological care and how EbGlyss addresses them, fostering evidence-based adoption and optimized patient outcomes.
This Activity for
- Resident / Fellow
- Physician
- Pharmacy
What I will learn?
•To educate HCPs on the scientific rationale behind IL-13 blockade and how it translates to clinical efficacy in atopic dermatitis.
•To familiarize clinicians with the pivotal clinical trials and real-world data supporting the use of EbGlyss.
•To provide clarity on patient selection and treatment optimization with EbGlyss.
•To encourage dialogue and knowledge exchange among experts regarding best practices in managing moderate-to-severe atopic dermatitis.
•To support the integration of EbGlyss into current treatment algorithms and national/international guidelines where applicable.
•To familiarize clinicians with the pivotal clinical trials and real-world data supporting the use of EbGlyss.
•To provide clarity on patient selection and treatment optimization with EbGlyss.
•To encourage dialogue and knowledge exchange among experts regarding best practices in managing moderate-to-severe atopic dermatitis.
•To support the integration of EbGlyss into current treatment algorithms and national/international guidelines where applicable.
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Ebglyss (Lebrikizumab) Launch KSA Certificate
Certificate |
Certificate | Free |
VAT 15% Included
